NEW YORK (GenomeWeb) – Aviva Systems Biology said today it has acquired protein tools firm GenWay Biotech.

In a statement, Aviva CEO Peter Jiang described the purchase as part of his company's larger plan to "become a leading provider of proteomic solutions," and cited GenWay's experience and assets in protein, antibody, and ELISA production for both the research and clinical markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.